A coimmunization vaccine of Aβ42 ameliorates cognitive deficits without brain inflammation in an Alzheimer’s disease model

INTRODUCTION: Vaccination against amyloid-β protein (Aβ42) induces high levels of antibody, making it a promising strategy for treating Alzheimer’s disease (AD). One drawback in the past was that clinical trial approval was withheld because of speculation that the Aβ42 vaccine induces CD4(+) T cell...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Wang, Shuang, Yu, Yang, Geng, Shuang, Wang, Dongmei, Zhang, Li, Xie, Xiaoping, Wu, Bing, Li, Chaofan, Xu, Hanqian, Li, Xiaolin, Hu, Yanxin, Zhang, Lianfeng, Kaether, Christoph, Wang, Bin
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2014
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4075150/
https://ncbi.nlm.nih.gov/pubmed/24987466
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/alzrt256
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars